Go Pro
→ Why major institutions are piling into this digital asset now (From Awesomely) (Ad)tc pixel Free MRV Stock Alerts

Nuvo Pharmaceuticals (MRV) Competitors

C$37.22 -1.28 (-3.32%)
As of 03:59 PM Eastern
Compare

MRV vs. APH, VRX, APHA, BHC, and MJN

Should you buy Nuvo Pharmaceuticals stock or one of its competitors? Nuvo Pharmaceuticals's main competitors and comparable companies include Aphria (APH), Valeant Pharmaceuticals International (VRX), Aphria (APHA), Bausch Health Companies (BHC), and Cronos Group (MJN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Nuvo Pharmaceuticals compare to Aphria?

Aphria (TSE:APH) and Nuvo Pharmaceuticals (TSE:MRV) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

In the previous week, Aphria's average media sentiment score of 0.00 equaled Nuvo Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Aphria Neutral
Nuvo Pharmaceuticals Neutral

Aphria has higher revenue and earnings than Nuvo Pharmaceuticals. Aphria is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AphriaC$29.01B0.98C$4.93BC$4.005.76
Nuvo PharmaceuticalsC$8.72B3.83C$15.17MC$2.9112.79

8.1% of Aphria shares are owned by institutional investors. Comparatively, 1.8% of Nuvo Pharmaceuticals shares are owned by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Aphria's net margin of 0.00%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Aphria's return on equity.

Company Net Margins Return on Equity Return on Assets
AphriaN/A N/A N/A
Nuvo Pharmaceuticals 20.95%1,180.47%5.85%

Aphria has a beta of 3.455044, suggesting that its stock price is 246% more volatile than the broader market. Comparatively, Nuvo Pharmaceuticals has a beta of 0.917796, suggesting that its stock price is 8% less volatile than the broader market.

Summary

Nuvo Pharmaceuticals beats Aphria on 6 of the 11 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Valeant Pharmaceuticals International?

Valeant Pharmaceuticals International (TSE:VRX) and Nuvo Pharmaceuticals (TSE:MRV) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

In the previous week, Valeant Pharmaceuticals International's average media sentiment score of 0.00 equaled Nuvo Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Valeant Pharmaceuticals International Neutral
Nuvo Pharmaceuticals Neutral

1.8% of Nuvo Pharmaceuticals shares are held by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Valeant Pharmaceuticals International's net margin of 0.00%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Valeant Pharmaceuticals International's return on equity.

Company Net Margins Return on Equity Return on Assets
Valeant Pharmaceuticals InternationalN/A N/A N/A
Nuvo Pharmaceuticals 20.95%1,180.47%5.85%

Nuvo Pharmaceuticals has higher revenue and earnings than Valeant Pharmaceuticals International.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Valeant Pharmaceuticals InternationalN/AN/AN/AN/AN/A
Nuvo PharmaceuticalsC$8.72B3.83C$15.17MC$2.9112.79

Summary

Nuvo Pharmaceuticals beats Valeant Pharmaceuticals International on 6 of the 6 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Aphria?

Nuvo Pharmaceuticals (TSE:MRV) and Aphria (TSE:APHA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Aphria's net margin of 0.00%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Aphria's return on equity.

Company Net Margins Return on Equity Return on Assets
Nuvo Pharmaceuticals20.95% 1,180.47% 5.85%
Aphria N/A N/A N/A

Nuvo Pharmaceuticals has higher revenue and earnings than Aphria. Aphria is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvo PharmaceuticalsC$8.72B3.83C$15.17MC$2.9112.79
AphriaC$611.06M0.00-C$637.39M-C$2.01N/A

1.8% of Nuvo Pharmaceuticals shares are held by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Nuvo Pharmaceuticals' average media sentiment score of 0.00 equaled Aphria'saverage media sentiment score.

Company Overall Sentiment
Nuvo Pharmaceuticals Neutral
Aphria Neutral

Summary

Nuvo Pharmaceuticals beats Aphria on 9 of the 9 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Bausch Health Companies?

Bausch Health Companies (TSE:BHC) and Nuvo Pharmaceuticals (TSE:MRV) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

10.4% of Bausch Health Companies shares are held by institutional investors. Comparatively, 1.8% of Nuvo Pharmaceuticals shares are held by institutional investors. 11.3% of Bausch Health Companies shares are held by company insiders. Comparatively, 6.3% of Nuvo Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Bausch Health Companies had 14 more articles in the media than Nuvo Pharmaceuticals. MarketBeat recorded 14 mentions for Bausch Health Companies and 0 mentions for Nuvo Pharmaceuticals. Bausch Health Companies' average media sentiment score of 0.46 beat Nuvo Pharmaceuticals' score of 0.00 indicating that Bausch Health Companies is being referred to more favorably in the media.

Company Overall Sentiment
Bausch Health Companies Neutral
Nuvo Pharmaceuticals Neutral

Nuvo Pharmaceuticals has lower revenue, but higher earnings than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bausch Health CompaniesC$10.85B0.32-C$125.65M-C$2.94N/A
Nuvo PharmaceuticalsC$8.72B3.83C$15.17MC$2.9112.79

Bausch Health Companies has a beta of 0.959729, meaning that its stock price is 4% less volatile than the broader market. Comparatively, Nuvo Pharmaceuticals has a beta of 0.917796, meaning that its stock price is 8% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bausch Health Companies
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Nuvo Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Bausch Health Companies' net margin of -12.02%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Bausch Health Companies' return on equity.

Company Net Margins Return on Equity Return on Assets
Bausch Health Companies-12.02% 87.57% 4.16%
Nuvo Pharmaceuticals 20.95%1,180.47%5.85%

Summary

Bausch Health Companies and Nuvo Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Cronos Group?

Cronos Group (CVE:MJN) and Nuvo Pharmaceuticals (TSE:MRV) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

1.8% of Nuvo Pharmaceuticals shares are owned by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Cronos Group's net margin of 0.00%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Cronos Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Cronos GroupN/A N/A N/A
Nuvo Pharmaceuticals 20.95%1,180.47%5.85%

Nuvo Pharmaceuticals has higher revenue and earnings than Cronos Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos GroupN/AN/AN/AN/AN/A
Nuvo PharmaceuticalsC$8.72B3.83C$15.17MC$2.9112.79

In the previous week, Cronos Group had 1 more articles in the media than Nuvo Pharmaceuticals. MarketBeat recorded 1 mentions for Cronos Group and 0 mentions for Nuvo Pharmaceuticals. Cronos Group's average media sentiment score of 0.00 equaled Nuvo Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Cronos Group Neutral
Nuvo Pharmaceuticals Neutral

Summary

Nuvo Pharmaceuticals beats Cronos Group on 6 of the 7 factors compared between the two stocks.

Get Nuvo Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for MRV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MRV vs. The Competition

Export
MetricNuvo PharmaceuticalsPharmaceuticals IndustryHealthcare SectorTSE Exchange
Market CapC$33.41BC$12.42BC$7.29BC$12.58B
Dividend Yield0.03%2.62%2.54%6.22%
P/E Ratio12.79780.42271.3838.95
Price / Sales3.83785.30638.9510.07
Price / Cash0.2315.4729.0382.29
Price / Book49.6310.4211.184.80
Net IncomeC$15.17MC$2.79BC$3.46BC$299.09M
7 Day Performance-2.26%2.25%1.98%0.73%
1 Month Performance17.75%4.72%7.32%5.30%
1 Year PerformanceN/A7.07%24.76%34.77%

Nuvo Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MRV
Nuvo Pharmaceuticals
N/AC$37.22
-3.3%		N/AN/AC$33.41BC$8.72B12.79N/A
APH
Aphria
N/AC$22.78
-1.8%		N/AN/AC$28.09BC$29.01B5.7080,000
VRX
Valeant Pharmaceuticals International
N/AN/AN/AN/AC$10.76BN/AN/AN/A
APHA
Aphria
N/AN/AN/AN/AC$5.24BC$611.06MN/A1,200
BHC
Bausch Health Companies
0.9432 of 5 stars		C$9.41
-0.7%		N/A-15.0%C$3.52BC$10.85BN/A19,900

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:MRV) was last updated on 8/24/2026 by MarketBeat.com Staff.
From Our Partners
I found Rolls-Royce at $2 - now I see the same setup again
In 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...
Monument Traders Alliance | Sponsoredtc pixel
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...
Porter & Company | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Buy These Stocks Before August 31st
Keith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...
TradeSmith | Sponsoredtc pixel
Elon Musk’s Hushed FCC Filing. Sept 25th.
Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...
Paradigm Press | Sponsoredtc pixel
Gold majors have a big problem
Newmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...
Golden Portfolio | Sponsoredtc pixel